Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × Biopsy × Clear all

NCT07405476 2026-04-17

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05223036 2026-04-13

Testing Obeticholic Acid for Familial Adenomatous Polyposis

Phase 2 Suspended

Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05419011 2026-04-13

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT06557733 2026-04-13

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Phase 2 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT04767984 2026-01-21

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Phase 2 Active not recruiting

Gastrointestinal

Colitis, Ulcerative, Colorectal Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06425133 2024-12-24

CARE

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05518032 2024-09-26

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT00390364 2014-10-08

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Phase 2 Terminated

1 enrolled 7 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00513266 2009-08-07

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

Phase 2 Unknown

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms